These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 22534277)

  • 1. FPIN’s clinical inquiries. Medications for weight loss in patients with type 2 diabetes mellitus.
    Kachowski L; Over DR; Qiu K
    Am Fam Physician; 2012 Mar; 85(6):633-5. PubMed ID: 22534277
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term effects of weight-reducing drugs in people with hypertension.
    Siebenhofer A; Jeitler K; Horvath K; Berghold A; Posch N; Meschik J; Semlitsch T
    Cochrane Database Syst Rev; 2016 Mar; 3():CD007654. PubMed ID: 26934640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis.
    Norris SL; Zhang X; Avenell A; Gregg E; Schmid CH; Kim C; Lau J
    Arch Intern Med; 2004 Jul; 164(13):1395-404. PubMed ID: 15249348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacologic treatment of obesity.
    Sidhaye A; Cheskin LJ
    Adv Psychosom Med; 2006; 27():42-52. PubMed ID: 16418541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Add-on combination and maintenance treatment: case series of five obese patients with different eating behavior.
    Anghelescu I; Klawe C; Szegedi A
    J Clin Psychopharmacol; 2002 Oct; 22(5):521-4. PubMed ID: 12352278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of the overweight patient with Type 2 diabetes.
    Peter P; Kumar S
    Diabet Med; 2003 Sep; 20 Suppl 4():10-3. PubMed ID: 12940860
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus.
    Norris SL; Zhang X; Avenell A; Gregg E; Schmid CH; Lau J
    Cochrane Database Syst Rev; 2005 Jan; 2005(1):CD004096. PubMed ID: 15674929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Currently available drugs for the treatment of obesity: Sibutramine and orlistat.
    Chaput JP; St-Pierre S; Tremblay A
    Mini Rev Med Chem; 2007 Jan; 7(1):3-10. PubMed ID: 17266632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacotherapy for obesity: current drugs and those in advanced development.
    Halford JC
    Curr Drug Targets; 2004 Oct; 5(7):637-46. PubMed ID: 15473253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term pharmacotherapy for obesity and overweight.
    Padwal R; Li SK; Lau DC
    Cochrane Database Syst Rev; 2003; (4):CD004094. PubMed ID: 14584004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of antiobesity medications in patients with type 2 diabetes mellitus.
    Choussein S; Makri AA; Frangos CC; Petridou ET; Daskalopoulou SS
    Diabetes Obes Metab; 2009 Jul; 11(7):641-64. PubMed ID: 19236442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obesity.
    Arterburn D
    Clin Evid; 2004 Jun; (11):762-76. PubMed ID: 15652036
    [No Abstract]   [Full Text] [Related]  

  • 14. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity.
    Gokcel A; Gumurdulu Y; Karakose H; Melek Ertorer E; Tanaci N; BascilTutuncu N; Guvener N
    Diabetes Obes Metab; 2002 Jan; 4(1):49-55. PubMed ID: 11874442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
    Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
    Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Obesity drug therapy.
    Baretić M
    Minerva Endocrinol; 2013 Sep; 38(3):245-54. PubMed ID: 24126545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What are the risks and the benefits of current and emerging weight-loss medications?
    Robinson JR; Niswender KD
    Curr Diab Rep; 2009 Oct; 9(5):368-75. PubMed ID: 19793507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacotherapy for weight loss in patients with type 2 diabetes].
    Toubro S
    Ugeskr Laeger; 2007 Aug; 169(33):2619-22. PubMed ID: 17725907
    [No Abstract]   [Full Text] [Related]  

  • 19. Options for pharmacological management of obesity in patients treated with atypical antipsychotics.
    Werneke U; Taylor D; Sanders TA
    Int Clin Psychopharmacol; 2002 Jul; 17(4):145-60. PubMed ID: 12131598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [How safe are the new obesity drugs? Indications and contraindications of orlistat and sibutramine].
    Richter WO
    MMW Fortschr Med; 1999 Dec; 141(49-50):32-6. PubMed ID: 10726144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.